4.3 Article

The feasibility and safety of S-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Psychology, Clinical

Evidence for S-Adenosyl-L-Methionine (SAM-e) for the Treatment of Major Depressive Disorder

George I. Papakostas

JOURNAL OF CLINICAL PSYCHIATRY (2009)

Article Psychology, Developmental

Psychiatric Disorders and Intellectual Functioning Throughout Development in Velocardiofacial (22q11.2 Deletion) Syndrome

Tamar Green et al.

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2009)

Article Pediatrics

Manic symptoms and behavioral dysregulation in youth with velocardiofacial syndrome (22q11.2 deletion syndrome)

Alka Aneja et al.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2007)

Article Psychiatry

Genetic and neurochemical modulation of prefrontal cognitive functions in children

A Diamond et al.

AMERICAN JOURNAL OF PSYCHIATRY (2004)

Article Pharmacology & Pharmacy

Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans

JL Gören et al.

PHARMACOTHERAPY (2004)

Article Psychiatry

Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome

T van Amelsvoort et al.

SCHIZOPHRENIA RESEARCH (2004)

Article Behavioral Sciences

Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats

NS Lamango et al.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2000)